1. Establish an IgAN cohort collaboration group and expert committee to carry out registration research.
2. Construct IgAN structured data set standards, formulate structured data collection templates of diagnosis and treatment , and establish multi-center data integration systems on this basis.
3. Establish a standardized IgAN database for combined Hospital Information System and the big data platform of the Medical Federation.
4. Develop IgAN database managements and open standards for data sharing, and carry out high-quality clinical or basic research.
Eligibility
Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria:
1. No age limit, no gender limit;
2. Kidney biopsy confirmed primary IgA nephropathy;
3. Sign the informed consent form voluntarily
Exclusion Criteria:
1. IgA nephropathy is secondary to systemic diseases such as systemic lupus erythematosus and allergic purpura;
2. IgAN is clinically diagnosed but not confirmed by pathology;
3. The patient refuses to participate;
4. Patients judged by other investigators to be unsuitable for inclusion in the study.
Primary outcome measure(s)
The proportion of a decline in estimated glomerular filtration rate by > 50% from baseline — 1 year To evaluate the renal function
The proportion of doubling serum creatinine compared with baseline — 1 year To evaluate the renal function
Incidence of ESRD — 1 year To evaluate the renal function
Trial sites (1)
Facility
City
Region
Status
Ruijin Hospital, Shanghai JiaoTong University School of Medicine
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.